Clovis Oncology Investor Relations Material
Latest events
Q2 2022
Clovis Oncology
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Clovis Oncology Inc
Access all reports
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company's clinical trial programs comprise three drug candidates designed to inhibit the growth of cancer tumors. Its lead product candidate is NDA 20-538 for metastatic adenocarcinoma of the pancreas; and other preclinical assets include NK-1 receptor antagonists for the treatment of inflammatory bowel disease; glio-selectins for the treatment of glioblastoma multiforme; and JTK inhibitors for multiple indications. Clovis Oncology markets its products through a limited direct sales force in the majority of its markets. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States